Answers are grounded in this paper and cite their sources.
Introduction Gastric cancer (GC) is a leading cause of cancer-related death and a significant global health burden. Chemotherapy remains the mainstay of treatment in advanced disease and only trastuzumab in combination with upfront fluoropyrimidine/platinum chemotherapy for human epidermal growth factor receptor 2 (HER2) positive disease and ramucirumab together with paclitaxel in the second line have demonstrated a significant survival benefit over chemotherapy alone. Despite the focus on a molecularly targeted approach, treatment gains have been modest and GC remains an area of great unmet need.Areas covered In this review, we provide an overview of the continuum of care in GC, the molecular characterization of GC, targeted therapies currently under investigation and the role of immunotherapy.Expert commentary Gastric cancer is a heterogeneous disease. A targeted approach based upon molecular phenotype holds promise for improving outcomes.
No takes yet. Share an insight, caveat, or question.
Cartwright et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: